1.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 54 and under
Sponsor: Other
Protocol IDs: 0107M05202, MT2001-02, NCT00176930
|
|
2.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: MSKCC-95024, NCI-V95-0685, NCT00002663
|
|
3.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: FDA IND 100712, 96-MH-01, NCT00611208
|
|
4.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 25223, PSU25223, NCT00626626
|
|
5.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CINJ-050803, 050803, 7998, NCT00740805
|
|
6.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PCYC-0403, NCT00724984
|
|
7.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D1600C00001, 2008-002606-19, NCT00731263
|
|
8.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 6th radioimmunotherapy prot., EudraCT number: 2007-002762-35, NCT00761384
|
|
9.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 0711003269, NCT00785798
|
|
10.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VGFT-ST-0708, TCD10767, NCT00794417
|
|
11.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: ARL-GT 2005, NCT00858793
|
|
12.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 265-103, NCT00975767
|
|
13.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 9 and over
Sponsor: NCI
Protocol IDs: NCI-01-C-0030, NCI-2890, 2890, NCT00020384
|
|
14.
|
Phase: Phase II
Type: Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UHN REB 05-0339-C, NCT00188929
|
|
15.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 70
Sponsor: NCI
Protocol IDs: UMN-2005LS048, UMN-0508M72589, UMN-MT2004-24, NCT00345865
|
|
16.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: NU-06H2, NU-1346-018, ORTHO-NU-06H2, NCT00392990
|
|
17.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: AMC-048, AMC-048, NCT00392834
|
|
18.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 15 to 65
Sponsor: Other
Protocol IDs: C-012A, NCT00561301
|
|
19.
|
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: P071203, MnDPDP04, IDRCB 2008-A000198-39, NCT00727922
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: CPKC412D2201, NCT00782067
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 3 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: P2 L-D AB, NCT00917826
|
|
22.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 12 to 120
Sponsor: Pharmaceutical / Industry
Protocol IDs: SGN35-006, NCT00947856
|
|
23.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 64 and under
Sponsor: Other
Protocol IDs: FHCRC-2212.00, NCI-2009-01244, NCT00968630
|
|
24.
|
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 0908-04; IUCRO-0256, NCT00975975
|
|
25.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 09-0679-04, NCT00997386
|
